- Immunic ( NASDAQ: IMUX ) on Thursday said a phase 1b trial of its psoriasis treatment IMU-935 failed to separate from placebo, as measured by a reduction in the severity of the psoriatic lesions in the patients.
- Shares of the micro-cap clinical-stage biopharma plunged 73.7% to $2.49 after hours.
- A pre-planned interim analysis of the early-stage trial found a greater decrease than expected in the so-called Psoriasis Area and Severity Index (PASI) in the placebo arm.
- The PASI is a widely used instrument in psoriasis trials that evaluates and grades the severity of psoriatic lesions and the patient's response to treatment.
- The trial enrolled a total of 41 patients who were randomized to get 150 mg once-daily and 150 mg twice-daily doses of IMU-935, along with placebo.
- "At this point, the company only has access to very limited information. The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period. Immunic does not yet have access to unblinded individual patient data," the company said in a statement .
- IMUX expects to continue IMU-935 development in psoriasis.
For further details see:
Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo